Introduction
============

Depressive illness is a public health issue of major significance. Lifetime prevalence is estimated at about 15% and most depressed patients are treated in general practice.[@b1-ppa-6-087] Despite the proven efficacy of antidepressant medication, many depressed patients do not receive an adequate dosage and duration of treatment.[@b2-ppa-6-087] Shortcomings in treatment for depression are frequently noted both in primary care and specialized settings. The effectiveness of antidepressants is also reduced by patients' non-adherence. Observational studies found discontinuation rates of 28% at 1 month and 44% to 52% at 3 months.[@b3-ppa-6-087] Non-adherence may result in serious consequences such as treatment failure, relapse, a chronic course of depression, complications, high medical care utilization, increased costs, and impairment in work functioning and other activities.[@b3-ppa-6-087]

The role of pharmacists in the medical field has recently grown well beyond the dispensing function and expanded to clinical trials, health economics, patient education, and other related roles.[@b4-ppa-6-087] Pharmacist interventions have proved to be beneficial for improving treatment outcomes in a variety of healthcare settings.[@b5-ppa-6-087] Because of their excellent position of having direct patient contact, pharmacists can help patients to address barriers to adherence which may include, inter alia, concerns about adverse effects, increased duration of therapy, frequency of drug administration, cost-effectiveness, and pill burden; they incorporate interventions into the care of their patients with the use of different strategies such as patient education, drug monitoring, and management of adverse reactions.

Aims
====

The aim of this investigation was to systematically examine the published literature to explore different types of pharmacist interventions used in order to enhance patients' adherence to antidepressant medication. Three specific questions guided the review:

1.  What is the impact of pharmacist interventions on adherence to antidepressant medication?

2.  What is the impact of pharmacist interventions on patient-reported outcomes and patient satisfaction?

3.  What are the types of interventions used by pharmacists to enhance patients' adherence to antidepressants?

Methods
=======

A systematic review of the published literature was conducted to identify all studies that had examined pharmacist interventions to improve adherence to antidepressant medication published from 2000--2010. The reasons for selecting this cutoff period were: most studies focusing on pharmacists' interventions in patients with depression were conducted during this period; the role of pharmacists began to change and expand from just dispensing and compounding drugs to providing pharmaceutical care in the late 1990s and include reviewing of prescribed drugs, taking part in clinical rounds, becoming an important member of the clinical team, counseling in outpatient and inpatient settings, and others.[@b6-ppa-6-087]--[@b8-ppa-6-087] These papers were analyzed in line with qualitative review methodology to produce a number of data themes that were later grouped together to produce the dominant categories. In addition, the quality of the studies was assessed using the Jadad scale,[@b9-ppa-6-087] which is easy to use, contains many of the important elements that have empirically been shown to correlate with bias, has known reliability and external validity, and is most widely used worldwide for such assessments.[@b10-ppa-6-087] The Jadad scale is a three-item scale that considers three features of a study: randomization, double-blinding, and flow of patients. Adequate description of allocation concealment was also evaluated. Total summed scores ranged from 0 to 7, with the higher scores indicating higher quality.[@b11-ppa-6-087] However, blinding of pharmacists and participants was not possible because of the type of intervention assessed in this systematic review; therefore, total scores ranged from 0 to 5 ([Table 1](#t1-ppa-6-087){ref-type="table"}). Although the Jadad scale is a little out of date, it nonetheless still has all the statistical qualities and practical applications for assessing the quality of current randomized clinical trials.[@b12-ppa-6-087] In light of the more elaborate scales that are emerging, whether or not the use of the Jadad scale is a weakness or strength of this research is a moot point.[@b12-ppa-6-087]

Information sources and searches
--------------------------------

During August to November 2010, the following databases were searched for articles published between 2000 and 2010: PubMed, BIOSIS Previews, Web of Science, ScienceDirect, The Cochrane Library, PsycINFO, IngentaConnect, Cambridge Journals Online, and Medscape databases. A variety of key medical subject headings terms and text words were constructed for use within the databases: pharmacist intervention, medication intervention, depression, medication adherence, compliance, health-related quality of life, and patient-reported outcomes. The key words "pharmacist intervention" were then combined with "medication adherence", "antidepressant medications", "depression", "health quality", "patient-reported outcomes", "randomized clinical trials", "systematic reviews", and "quality reports" for the purpose of the second round of the computer search.

Notably, "adherence", "compliance", and "persistence" have different meanings when used stringently. Adherence to medication is defined as: "the extent to which a person's behavior, taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health-care provider".[@b25-ppa-6-087] The term "adherence" rather than "compliance" is now advocated because compliance implies that the instructions of the health-care provider have to be followed in a passive way and that the patient is not expected to engage in a therapeutic association or any agreement with the healthcare provider.[@b26-ppa-6-087] On the other hand, persistence is described as continuous refilling of prescriptions in accordance with the suggested duration of the therapy, which is determined by evaluating solely whether or not the patient continues treatment.[@b27-ppa-6-087] In general, pharmacists' interventions usually focus on medication; consequently, adherence is the primary outcome in most of these studies. For this particular reason, the two reviewers decided to focus on medication adherence rather than compliance or persistence in this systematic review.

Study selection
---------------

The titles and abstracts of all articles were scanned for randomized control studies that had investigated the impact of pharmacists' intervention on patient adherence to antidepressant medication published from 2000 to 2010. The abstracts and studies were screened then discarded if they did not fit the selection criteria ([Table 2](#t2-ppa-6-087){ref-type="table"}). Studies that were identified as potentially relevant were retrieved where possible and further screened for relevance. A total of 119 papers were retrieved, with 94 excluded on the basis of abstract review and 13 after full-text analysis, resulting in the retention of 12 studies suitable for inclusion. The papers were analyzed qualitatively by applying the Jadad scale. The methodology for research that had been adopted in papers included in this review was that of randomized controlled trials. This is because randomized controlled trials are considered to be the optimal study design for minimizing bias and providing the most accurate estimate of complex interventions in terms of benefits; also, it is the only trial design to establish causal effects.[@b28-ppa-6-087]

Inclusion criteria
------------------

The considered inclusion criteria were as follows: published in English language; study is primary in nature; published in a peer-reviewed journal; full-text articles and publication dates match the years lying between 2000 to 2010; study design a randomized control study; recruited to investigate depressed adult patients, and the main outcome finding adherence to antidepressant medications.

Exclusion criteria
------------------

Studies without control groups or randomization, descriptive studies, pilot studies, results of postal surveys, and qualitative interviews were excluded from this review. Non-English papers were also discarded to prevent cultural and linguistic bias in translation. Studies were also excluded if the pharmacist was not involved in the intervention or service provided to patients. In addition, papers were excluded if no participants in the sample were diagnosed with depression. Other exclusion criteria were depressed adolescent patients, editorials, book chapters and duplicate articles, and systematic reviews, and if the focus of the study was not on adherence. Each study meeting the inclusion and exclusion criteria was sorted on the basis of the pharmacist intervention, sample size, follow-up, outcome measures, findings, country of origin, setting, and number of involved pharmacists.

Data abstraction
----------------

A grid was created to record the summaries of the articles for further conceptualization of the literature and later construction of the literature review. PICOS (participants, interventions, comparisons, outcomes, and study design) was used for data extraction. This initial tabulation presented information about the study characteristics, including the year of the study, the number of participants, type of intervention, comparison, country, research design, outcomes, and a brief description of study aims. For the main analysis, data from the findings of these original studies were summarized into a model to display the themes that presented the type of pharmacist intervention, patients' outcome measures, and change in adherence rate. Data from each study were extracted and checked independently by the two reviewers. Any point of inconsistency was discussed between the two investigators in order to reach 100% agreement regarding data abstracted from the selected studies.

Results
=======

The search yielded 119 citations. Of these, 94 studies were excluded after review of the title and abstract ([Figure 1](#f1-ppa-6-087){ref-type="fig"}). Of the remaining 25 studies, 13 studies were excluded because they did not meet the inclusion criteria for method design, or the intervention was conducted by non pharmacists, or focused on other patient groups. Twelve studies met the criteria for inclusion in this review and were, therefore, selected for analysis. This section summarizes the results of the 12 core studies, which investigated pharmacists' intervention to enhance patients' adherence to antidepressant medication and related patient outcomes. A summary of findings from these peer-reviewed papers is shown in [Tables 2](#t2-ppa-6-087){ref-type="table"}--[6](#t6-ppa-6-087){ref-type="table"}. The 12 included studies published between 2000 and 2010 were carried out in the USA, Canada, the Netherlands, Australia, and Kuwait.

Quality of included studies
---------------------------

Twelve studies met the criteria for inclusion in this review and were therefore selected for analysis ([Table 2](#t2-ppa-6-087){ref-type="table"}). No systematic reviews were identified. All investigations were presented as original research papers published in peer-reviewed indexed journals. While only one study investigated the impact of pharmacist intervention in inpatient sites, the remaining investigations were conducted in either community pharmacies or primary care pharmacy settings.

All studies involved patients with depression and pharmacist interventions. In toto, 1904 patients and 136 pharmacists participated in the selected studies, which had short follow-up; only two studies continued up to 12 months.[@b17-ppa-6-087],[@b18-ppa-6-087] Moreover, in all of these trials neither patients nor pharmacists were blinded, which led to a decrease in the quality of studies, ie, a score less than 5 in terms of the Jadad scale.

The majority of the studies involved fewer than seven pharmacists, and four papers described interventions by just two pharmacists.[@b13-ppa-6-087],[@b15-ppa-6-087],[@b18-ppa-6-087],[@b29-ppa-6-087] Although involving small numbers of pharmacists may make for good internal consistency, the results obtained may not be generalizable to the outcomes of services provided by the wider pharmacy profession. Overall, the studies involved a pharmacist--patient ratio of 1:14, which is not commensurate with clinical practice.

Methodological quality ranged from 2 to 5 on the Jadad scale, and nine of the studies scored 3 or more which represents high-quality studies with adequate randomization, flow, and fate of all patients in the trial known; in case of no data, the reasons were stated. The most commonly absent item was an adequate description of concealment of allocation. Only two studies[@b18-ppa-6-087],[@b22-ppa-6-087] -- which had a score of less than 3 on the Jadad scale and hence reflected poor-quality research -- reasonably reported no change in adherence rate.

Adherence to antidepressants
----------------------------

Researchers utilized numerous measurements to measure the change of medication adherence in these papers: patient self-reports (n = 6), pill counts (n = 3), prescription claims (n = 2), and an electronic pill container (n = 1). This led to the widely mixed results observed in these papers. All the investigators during the study included one method to measure the change in adherence either subjectively or objectively.

The impact of interventions by pharmacists on medication adherence as outlined in the studies in this review is summarized in [Table 3](#t3-ppa-6-087){ref-type="table"}. Seven investigations reported an improvement in patients' adherence and two studies reported no significant change in patients' adherence between control and tested groups; only three studies reported no change in adherence rate. All the latter three studies were conducted in an outpatient setting with a relatively small sample size reflecting an underpowered study.[@b18-ppa-6-087],[@b22-ppa-6-087],[@b24-ppa-6-087] Notably, two of the studies[@b18-ppa-6-087],[@b19-ppa-6-087] that failed to show differences in effect on patients' adherence had multiple interventions, ie, three or more different types of intervention.

Impact of intervention on patients' reported outcomes and depression severity
-----------------------------------------------------------------------------

According to this systematic review, the majority of the papers monitored psychological dimensions such as depressive symptoms, mood, satisfaction, knowledge, and others. Eight studies measured depressive symptoms and six of them reported no statistical difference in improvement in depressive symptoms between the pharmacist intervention group and the control group. Only two studies[@b13-ppa-6-087],[@b24-ppa-6-087] reported improvement in depressive symptoms at various levels using various measures. Only four studies[@b13-ppa-6-087],[@b14-ppa-6-087],[@b16-ppa-6-087],[@b21-ppa-6-087] reported an improvement in patients' satisfaction with the treatment and three studies reported a change in patients drug knowledge[@b14-ppa-6-087],[@b19-ppa-6-087],[@b21-ppa-6-087] after pharmacist intervention. The improvement in depression severity and patients' reported outcomes are summarized in [Table 4](#t4-ppa-6-087){ref-type="table"}, with an in-depth analysis of these studies shown in [Table 5](#t5-ppa-6-087){ref-type="table"}.

Types of pharmacist intervention
--------------------------------

Five different types of pharmacist intervention were implemented in studies included in this review, which were as follows: (1) educating and counseling patients about the importance of adherence, explaining the side effects of medications and reviewing regimens; (2) monitoring drugs and following up drug reactions; (3) prescribing drug and dose changes to simplify regimens under protocol; (4) following up patients by phone calls and providing all information and response to patients enquiries, and (5) educating patients by providing a take-home video emphasizing the importance of medication adherence.[@b13-ppa-6-087]--[@b24-ppa-6-087] The most common intervention strategy that pharmacists utilized was a combination of drug monitoring, drug counseling, and patient education. Four studies reported that pharmacists were authorized to prescribe medications and change doses under the supervision of psychiatrists or physicians.

A telephone call or a reminder was found to be an effective approach to improve medication adherence ([Table 6](#t6-ppa-6-087){ref-type="table"}). Five of six studies that included telephone contact with patients in the intervention reported a substantial improvement in medication adherence. The results of the only study that reported no significant change in adherence[@b18-ppa-6-087] were probably due to a high adherence rate in the control group; a low ratio of pharmacists' contact with patients that is one contact every 3 months, and an underpowered sample size (n = 74). However, the strategy of telephone support is limited in the extent to which it can be generalized for clinical practices because of time and cost considerations. Telephone contact can also be a barrier to clear communication and thus may affect the patients' level of understanding.

Five studies assessed the impact of pharmacist intervention by providing patient education and monitoring.[@b13-ppa-6-087],[@b16-ppa-6-087]--[@b19-ppa-6-087] Four of the five studies demonstrated that involvement of the pharmacist was associated with a significant improvement in medication adherence.[@b13-ppa-6-087],[@b16-ppa-6-087],[@b17-ppa-6-087],[@b19-ppa-6-087] Again, it was the study reported by Capoccia and associates[@b18-ppa-6-087] that found no significant change in adherence, which can be related to the aforementioned factors. The general findings from previous literature intervention studies and this review have shown that psychoeducation is an effective means of enhancing treatment adherence by offering structured and detailed information to patients about their treatments.[@b3-ppa-6-087],[@b30-ppa-6-087]--[@b32-ppa-6-087] This positive outcome may also be related to patients' ever-changing belief systems about their antidepressant medications.[@b33-ppa-6-087]

Discussion
==========

The challenge of evaluating complex and multifactorial pharmacist interventions with a combination of different adherence strategies has resulted in mixed outcomes and made it difficult to identify the most effective role that pharmacists may assume. In addition, heterogeneity in pharmacist interventions, treatment settings, patient populations, and measured outcomes is apparently large enough to discourage a meta-analysis of these findings.

This systematic review addressed an important role of pharmacists in providing pharmaceutical care to patients with depression. This critical narrative review revealed a positive effect of pharmacist interventions on antidepressant medication adherence by patients. The findings of this study are consistent with those of other researchers.[@b34-ppa-6-087] In addition to revealing a positive effect of pharmacists' intervention; this review also substantiated claims of improved medication adherence among depressed people who were treated by antidepressant medications prescribed by community mental health teams in Australia.[@b34-ppa-6-087]

There are some limitations in this research. Firstly, though a positive outcome in patient adherence to antidepressant medication was identified, it is unclear whether or not this will result in an improvement in depressive symptoms. However, previous studies have reported a positive association between improved antidepressant medication adherence and depressive symptoms, attributed to substantial changes in adherence to antidepressant medications.[@b35-ppa-6-087] Secondly, the randomized controlled trials included had different methodological approaches, such as the pharmacy settings in terms of outpatient and inpatient pharmacy, type of diagnostic measures, adherence measures, and types of intervention performed. The different methodologies applied in the reviewed studies make the interpretation of results difficult. Thirdly, no study measured the relation between the change in adherence and relapse of depression because most studies were of less than 7 months' duration. It has been suggested that in order to assess the effectiveness of an intervention on relapse of depression, the intervention and follow-up duration should be extended to at least 2 years.[@b12-ppa-6-087] Largely, a 6-month follow-up period is a short time when referring to antidepressant treatment given to patients with multiple relapses of depression. This period needs to be extended to at least 6 months when remission of an episode of depression is expected. However, evidently dropouts occur mostly at the beginning of treatment with antidepressant medications. In some trials, the 2-month follow-up period did not alter the results including effect sizes.[@b22-ppa-6-087]

Fourthly, the included studies used different medication adherence measures as there is no cornerstone measurement for medication adherence. The objective (pill counts, electronic monitoring, and monitoring blood plasma concentration) versus subjective (self-administered questionnaires, self-reports, and physicians evaluation reports) medication adherence measurements tend to cause varied results in medication adherence studies. However, limiting the measurement to just one method increases the possibility of imprecise measurement of changes in adherence, while using two methods will overcome the disadvantage of each method alone. Only Al-Saffar and colleagues[@b21-ppa-6-087] utilized two methods: tablet counting and patient self-report. For instance, Velligan et al[@b36-ppa-6-087] reported that the data from objective measurements to oral antipsychotic medications were strongly correlated (r\[k\] = 0.61) but subjective measurements were weakly correlated with objective measurements, when adherence scores were examined by rank-order correlations (r\[k\] = 0.18--0.32). Blood plasma concentrations, an objective measurement, were not correlated with any other measures of adherence (kappa ≤ 20). They also found that the data from subjective measurement reports were best correlated with clinical state, which can be reliably utilized in daily clinical practices.

Fifthly, most of the included articles were published in pharmacy journals, ie, nine out of 12; it is quite possible that a publication bias influenced this trend. The majority of the studies involved compared the effectiveness of intervention between pharmacists' intervention group and usual care control group. However, none of these studies directly compared the effectiveness of intervention between pharmacists and other healthcare providers. Adverse drug side effects was cited as the leading cause of early discontinuation of medication and non-adherence to treatment: none of these studies indicated pharmacist intervention to manage these side effects.

Finally, in spite of these limitations, this study is, to the best of our knowledge, the first published systematic review of pharmacist interventions in patients with depression. Our review indicates that pharmacist interventions can improve patient adherence to antidepressant medications and also highlights the role of pharmacists in psychiatric pharmaceutical care services. These data show that patient counseling and treatment monitoring conducted by pharmacists can improve adherence to antidepressant medication.

Conclusion
==========

This systematic review of the literature highlighted the expanded roles of pharmacists, especially their interventions in the management of patients with depression in particular adherence to drug regimen. Notably, the data showed that patient counseling and treatment monitoring conducted by pharmacists can improve adherence to antidepressant medications. Pharmacist-conducted medication reviews and resulting recommendations to optimize medication use by patients with depression may reduce the complexity of the medication regimen and adherence. The available published evidence-based data tend to support the continued expansion of the pharmacist's role in the care of patients with depression and adherence to the treatment. Further studies are needed to assess the clinical outcomes of innovative pharmacist interventions based on theories that can explain the outcome and mechanisms of change with regard to patient adherence to medication. In summary, evidence from the studies reviewed strongly support the role of pharmacists in providing different types of interventions to improve medication adherence to antidepressant treatment by patients with depression in different settings.

Special note
------------

In major psychiatric treatment settings in the Kingdom of Saudi Arabia, pharmacist clinics have been established to provide counseling, review of prescribed medications, and collaborative management of the adverse effects of psychotropic drugs in outpatient settings. In addition, clinical pharmacists are important active players in multidisciplinary clinical teams that undertake regular rounds of inpatients and discuss different issues, including medications. Pharmacists contribute to the safe prescription and dispensing of drugs to health consumers, coupled with brief counseling focusing on adherence to treatment and its benefits. There is no database regarding their multiple roles and their effectiveness in clinical pharmacy services. Therefore, it would be timely to conduct studies in the Kingdom of Saudi Arabia that focus on pharmacist interventions and how to enhance medication adherence in the psychiatric population in general but in particular in patients with depression.
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###### 

Quality of studies using the Jadad scale for reporting randomized controlled trials

  Studies                     Adequate description of allocation concealment   Flow of patients is described and adequate   Flow of patients is described   Method of blinding is appropriate   Blinding is mentioned   Method of randomization is appropriate   Randomization is mentioned   Total
  --------------------------- ------------------------------------------------ -------------------------------------------- ------------------------------- ----------------------------------- ----------------------- ---------------------------------------- ---------------------------- -------
  Canales[@b13-ppa-6-087]     0                                                1                                            1                               0                                   0                       0                                        1                            3
  Bultman[@b14-ppa-6-087]     1                                                0                                            1                               0                                   0                       0                                        1                            3
  Finley[@b15-ppa-6-087]      0                                                1                                            1                               0                                   0                       0                                        1                            3
  Finley[@b16-ppa-6-087]      0                                                1                                            1                               0                                   0                       1                                        1                            4
  Adler[@b17-ppa-6-087]       1                                                1                                            1                               0                                   0                       1                                        1                            5
  Capoccia[@b18-ppa-6-087]    0                                                0                                            1                               0                                   0                       0                                        1                            2
  Rickles[@b19-ppa-6-087]     1                                                1                                            1                               0                                   0                       1                                        1                            5
  Brook[@b20-ppa-6-087]       0                                                1                                            1                               0                                   0                       0                                        1                            3
  Al-Saffar[@b21-ppa-6-087]   0                                                1                                            1                               0                                   0                       1                                        1                            4
  Crockett[@b22-ppa-6-087]    0                                                0                                            1                               0                                   0                       0                                        1                            2
  Rickles[@b23-ppa-6-087]     1                                                1                                            1                               0                                   0                       1                                        1                            5
  Bosmans[@b24-ppa-6-087]     1                                                1                                            1                               0                                   0                       0                                        1                            4

###### 

Summary of studies included in this review, 2000--2010

  Study                       Methodology                                                                                                                                                           Study location               Sample size   Brief description of study aims
  --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Canales[@b13-ppa-6-087]     Carried out in two phases. Control and experimental groups                                                                                                            Texas, USA                   93            To determine the effects of a psychiatric pharmacist on clinical outcomes of acute care psychiatric inpatients. and to monitor hospitalization costs
  Bultman[@b14-ppa-6-087]     Systematic, random sample of pharmacies and field study, interviewed patients                                                                                         Wisconsin, USA               100           To examine the effects of pharmacist monitoring on patient satisfaction and adherence to antidepressant medication therapy
  Finley[@b15-ppa-6-087]      Pharmacist follow-up of patients for 6 months through a combination of scheduled office visits and telephone calls. Working closely with psychiatric liaisons         California, USA              220           To examine efforts to improve patient adherence to antidepressant drug therapy and outcomes
  Finley[@b16-ppa-6-087]      A randomized controlled trial comparing the outcomes of subjects treated in care model intervention with subjects receiving usual care                                California, USA              150           To measure the effects of a collaborative care model that emphasized the role of clinical pharmacists in providing drug therapy management and treatment follow-up to patients with depression
  Adler[@b17-ppa-6-087]       A randomized clinical trial of a pharmacist intervention for depressed patients reporting antidepressant use and depression severity outcomes at 6 months             Massachusetts, USA           533           To evaluate outcomes of a pharmacist intervention for depressed patients in primary care
  Capoccia[@b18-ppa-6-087]    Randomized to enhanced care or usual care for 1 year                                                                                                                  Washington, USA              74            To evaluate the impact of pharmacist interventions in collaborative care to improve the care of and outcomes for patients with depression, to test the effectiveness of pharmacist interventions in the collaboration model
  Rickles[@b19-ppa-6-087]     Randomized, controlled unblended, mixed experimental design                                                                                                           Wisconsin, USA               63            To explore the impact of telephonebased education and monitoring by community pharmacists on multiple outcomes of pharmacist--patient collaboration
  Brook[@b20-ppa-6-087]       Randomized controlled trial with 6-month follow-up                                                                                                                    The Netherlands              147           To improve adherence to antidepressant regimens through pharmacist intervention
  Crockett[@b22-ppa-6-087]    Parallel-groups design with a control and intervention group                                                                                                          New South Wales, Australia   106           Documentation and evaluation of patient outcomes into the role of rural community pharmacists in the management of depression
  Rickles[@b23-ppa-6-087]     Randomized controlled, experimental design                                                                                                                            Wisconsin, USA               60            To determine whether or not telephone follow-up can influence the nature and extent to which antidepressant users provide feedback to pharmacists, whether patient characteristics are associated with the extent of patient feedback, how patient feedback affects subsequent outcomes after controlling for patient characteristics
  Bosmans[@b24-ppa-6-087]     An economic evaluation performed alongside a 6-month randomized controlled trial                                                                                      The Netherlands              88            To evaluate the cost-effectiveness of a pharmacy-based intervention to improve adherence to antidepressant therapy in adult patients receiving treatment in primary care
  Al-Saffar[@b21-ppa-6-087]   Randomized into a control and two treatment groups. Treatment groups additionally received a patient information leaflet. Adherence was monitored at 2 and 5 months   Kuwait                       270           To assess the acceptability and effectiveness of two educational initiatives on patterns of antidepressant medication use among depressed Kuwaiti patients

###### 

Impact of pharmacist intervention on adherence to antidepressant medication

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         Pharmacist intervention                                                                                                                                                                                                                             Adherence measures                             Outcomes                                                                                                                                                                                                                                                                    Rate of adherence   
  ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- -------
  Canales[@b13-ppa-6-087]       Monitoring drug reactions, conducting patient drug education weekly, and counseling                                                                                                                                                                 Barnes rating scale                            A significant improvement in adherence rate up to 27%                                                                                                                                                                                                                       27%                 −7%

  Simpson--Angus rating scale   22%                                                                                                                                                                                                                                                 −7%                                                                                                                                                                                                                                                                                                                                            

  Bultman[@b14-ppa-6-087]       Performing patient interviews to assess medication history, drug knowledge and drug belief, patient satisfaction, medication adherence                                                                                                              Health communication model                     Medication adherence rate was observed to be 76% within 3 months.24% of patients reported discontinuation of medication within 3 months.Pharmacist monitoring positively influenced adherence for patients taking antidepressants for the first time.                       63%                 87%

  Finley[@b15-ppa-6-087]        Intake and follow-up interviews (three clinic visits and five telephone calls); drug prescribing and dose changes under protocol; drug information counseling                                                                                       Prescription refills, clinic visit frequency   Medication adherence rate improved 15% at end of study (81% vs 66%).Patient's recall to complete 6-month treatment was different (76% vs 49%).Clinic visit decline was different (39% vs 12%).                                                                              81%                 66%

  Finley[@b16-ppa-6-087]        Drug monitoring; patient education; routine follow-up extensive phone calls at weeks 1, 2, 4, 10, and 16; Drug prescribing and medication change under protocol                                                                                     Prescription refills, clinic visit frequency   Medication adherence rate increased by 19% (67% vs 48%).Clinic visits declined by 13% (15% vs 2%).                                                                                                                                                                          67%                 48%

  Adler[@b17-ppa-6-087]         Contacting patients nine times over the 18-month study; monitoring drug treatment; educating patients to maintain antidepressant medication                                                                                                         Antidepressant use rate                        Intervention improved antidepressant adherence by \>11% at both 3 months (60.6 vs 48.9) and at 6 months (57.5 vs 46.2).For patients using antidepressants at study entry, no significant differences in antidepressant use were observed between groups at 3 or 6 months.   60.6%               48.9%

  Capoccia[@b18-ppa-6-087]      Performing patient follow-up by phone, interviewing patients twice during clinic visits.\                                                                                                                                                           Patient self-report\                           No significant difference in medication adherence between treatment groups.No difference between the two groups in number of visits to all health care providers was observed.                                                                                              59%                 57%
                                Patient contact during clinic visits (weeks 4 and 12); monitoring drug treatment; educating patients; providing drug refills and medication-dose adjustment                                                                                         Clinical visits                                                                                                                                                                                                                                                                                                                                

  Rickles[@b23-ppa-6-087]       Conducting three monthly phone calls to patients: during first call, assessing patient's drug knowledge and belief, adverse effects, drug use status, treatment goals, and self-rated depression severity; follow up during second and third call   Frequency of feedback to pharmacist            No significant difference between two groups in adherence rate was observed for the 3-month period.Rate of missed doses was significantly lower in the intervention group at 6 months (30% vs 49%)                                                                          70%                 51%

  Brook[@b20-ppa-6-087]         Offered three telephone calls (10--20 minutes); provided a take-home video emphasizing medication adherence; documented number of pills and refill date                                                                                             Pills consumed/day                             No differences in improvement in adherence rate was observed between two groups per intention-to-treat analysis.Adherence rate improved 17% (90% vs 73%) per intervention protocol analysis.                                                                                90%                 73%

  Crockett[@b22-ppa-6-087]      Pharmacists were given video-conference training on the nature and management of depression by a psychiatrist, psychologist, and general practitioner and asked to dispense medication with extra advice and support                                Patient self-report                            Adherence to medications was high in both groups (95% vs 96%)                                                                                                                                                                                                               95%                 96%

  Rickles[@b23-ppa-6-087]       Three monthly telephone calls from pharmacists providing structured education and monitoring                                                                                                                                                        Percentage of missed doses                     Significantly more feedback to pharmacists regarding different aspects of their antidepressant therapy                                                                                                                                                                                          

  Bosmans[@b24-ppa-6-087]       Offered three education and coaching programs and a take-home video reviewing important facts on depression and antidepressant drugs                                                                                                                Electronic pill container                      There were no significant differences in adherence                                                                                                                                                                                                                          88%                 86%

  Al-Saffar[@b21-ppa-6-087]     Patients received a patient information leaflet written in Arabic with counseling                                                                                                                                                                   Patient self-report                            Good medication adherence at 2 and 5 months was more common in patients who were given a patient information leaflet (odds ratio 3.0, confidence interval 1.7--5.3) or a patient information leaflet plus counseling (odds ratio 5.5, confidence interval 3.2--9.6)         39%                 10%

  Tablet counting               43%                                                                                                                                                                                                                                                 10%                                                                                                                                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Impact of pharmacist intervention on patient reported outcome and depression

  Study                       Pharmacist intervention                                                                                                                                                                                                                                                                                                           Outcome measures                                                                                     Significant outcomes
  --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Canales[@b13-ppa-6-087]     Performing baseline assessment and weekly review; reviewing medical history and drug administration records; monitoring drug reactions; providing treatment recommendation; conducting patient drug education weekly and counseling                                                                                               Depressive symptoms; cognitive function; quality of life; thought disorder; mood disorder            Hamilton Psychiatric Rating scores improved significantly for mood disorder (65% vs 9%)Discharge scores (thought disorder) improved significantly more in the intervention group (93% vs 23% for patients with 20% improvement and 62% vs 0% for 30% improvement)
  Bultman[@b14-ppa-6-087]     Performing patient interviews twice to assess medication history, drug knowledge, and drug belief, patient satisfaction, medication adherence and monitoring patient behavior                                                                                                                                                     Patient beliefs; patient knowledge; patient satisfaction with therapy; and adherence rate            High percentage (87%) of patients satisfied with antidepressant treatment at baselinePharmacist monitoring positively influenced adherence for patients taking antidepressants for the first time
  Finley[@b15-ppa-6-087]      Intake and follow-up interviews (three clinic visits and five phone calls); medical history review; drug prescribing and dose changes under protocol; drug information counseling                                                                                                                                                 Patient satisfaction; clinic visit frequency; Resource utilization                                   Clinic visit decline was different (39% vs 12%)Patients were more satisfied in intervention group
  Finley[@b16-ppa-6-087]      Drug monitoring; patient education; routine follow-up extensive phone calls at weeks 1, 2, 4, 10, and 16; drug prescribing and medication change under protocol                                                                                                                                                                   Patient satisfaction; clinic visit frequency; resource utilization                                   Intervention patients were more satisfied with treatmentClinic visits declined by 13% (15% vs 2%)Drug cost of intervention patients increased by 42%No significant difference in improvement of depressive symptoms
  Adler[@b17-ppa-6-087]       Contacting patients nine times over the 18-month study; reviewing medication history, drug side effects and efficacy; assisting drug choice, dose, and regimen; providing social support; educating patients to maintain medication                                                                                               Depression severity                                                                                  For patients using antidepressants at study entry, no significant differences in antidepressant use were observed between groups at 3 or 6 monthsFor patients not on antidepressants at study entry, antidepressant use rate was higher in intervention patients at both 3 months and 6 months
  Capoccia[@b18-ppa-6-087]    Performing patient follow-up by phone Interviewing patients two times during clinic visits; patient contact during clinic visits (weeks 4 and 12); monitoring drug treatment (time drugs taken, change of drugs and other treatment); educating patients on side effects; providing drug refills and medication dose adjustment   Depressive symptoms; patient satisfaction, and clinical visits                                       No overall difference in satisfaction with depression careNo overall difference in improvement of depression symptoms was observed between groupsNo difference between the two groups in number of visits to all health care providers was observed
  Rickles[@b19-ppa-6-087]     Conducting three monthly phone calls to patients: during first call, assessing patient's drug knowledge and belief, adverse effects, drug use status, treatment goals, and self-rated depression severity; follow-up during second and third call.                                                                                Frequency of feedback to pharmacist; depressive symptoms; antidepressant knowledge and drug belief   No statistically significant impact on depressive symptomsDepressive symptoms improved in both groupsIntervention patients had higher scores in drug knowledge and belief (75% vs 48%)
  Brook[@b20-ppa-6-087]       Offered three phone calls (10--20 minutes); Provided a take-home video emphasizing medication adherence; documented number of pills and refill date                                                                                                                                                                               Depressive symptoms                                                                                  No improvement in depressive symptoms was observed
  Al-Saffar[@b21-ppa-6-087]   Patients received a patient information leaflet written in Arabic with counseling                                                                                                                                                                                                                                                 Interview questionnaires                                                                             Patients in the treatment groups had an improved knowledge of the rationale of treatmentClinic attendance was more likely when patients had received interventionPreexisting patient attitudes to therapy and the occurrence of side effects were not determinants of adherence
  Crockett[@b22-ppa-6-087]    Pharmacists were given video-conference training on the nature and management of depression by a psychiatrist, psychologist and general practitioner and asked to dispense medication with extra advice and support                                                                                                               K10 and Drug Attitude Index                                                                          Both groups had improved significantly in well-being (a reduction K10 score of 4 (control) versus 4.7 (intervention))No significant change was found in attitude to drug treatment once baseline scores were controlled for
  Rickles[@b23-ppa-6-087]     Three monthly telephone calls from pharmacists providing structured education and monitoring                                                                                                                                                                                                                                      Frequency of patient feedback to pharmacists, antidepressant knowledge, depressive symptoms          Significantly more feedback to pharmacists regarding different aspects of their antidepressant therapy
  Bosmans[@b24-ppa-6-087]     Offered three education and coaching programs and a take-home video reviewing important facts on depression and antidepressant treatment                                                                                                                                                                                          Hopkins Symptom Checklist                                                                            Improvements in the Hopkins Symptom Checklist depression mean item score and costs

###### 

Detailed information about studies included in this review, 2000--2010

  Study                       Type of publication                                                                Year of publication   Year study conducted                                         Methodology                                                                                                                                          Study location               Setting                 Study participants   Sample size   Brief description of study aims
  --------------------------- ---------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------- -------------------- ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Canales[@b13-ppa-6-087]     Paper published in indexed American Journal of Health-System Pharmacy              2001                  October 1996 to December 1997                                Carried out in two phases; control and experimental groups                                                                                           Texas, USA                   Inpatient               2                    93            To determine the effects of a psychiatric pharmacist on clinical outcomes of acute care psychiatric inpatients and to monitor hospitalization costs
  Bultman[@b14-ppa-6-087]     Paper published in indexed Journal of the American Pharmacists Association         2002                  November 1995 to July 1996                                   Systematic, random sample of pharmacies and field study, patients were interviewed two times during the study                                        Wisconsin, USA               Community pharmacy      23                   100           To examine the effects of pharmacist monitoring on patient satisfaction and adherence to antidepressant medication therapy
  Finley[@b15-ppa-6-087]      Paper published in indexed American Journal of Health-System Pharmacy              2002                  July 1999 to June 2000, 10 months enrolment phase            Pharmacist follows up the patients through a combination of scheduled office visits and telephone calls. Working closely with psychiatric liaisons   California, USA              Primary care pharmacy   2                    220           To examine effort to improve patient adherence to antidepressant drug therapy and outcomes
  Finley[@b16-ppa-6-087]      Paper published in indexed Pharmacotherapy                                         2003                  Study conducted for 15 months, 9 months enrolment phase      A randomized controlled trial, compared the outcomes of intervention in care model with subjects receiving usual care                                California, USA              Primary care pharmacy   2                    150           To measure the effects of a collaborative care model that emphasized the role of clinical pharmacists in providing drug therapy management and treatment follow-up to patients with depression
  Adler[@b17-ppa-6-087]       Paper published in indexed General Hospital Psychiatry                             2004                  1998 to 2000                                                 A randomized clinical trial of a pharmacist intervention for depressed patients, report antidepressant use and depression severity outcomes          Massachusetts, USA           Primary care pharmacy   5                    533           To evaluate outcomes of a pharmacist intervention for depressed patients in primary care
  Capoccia[@b18-ppa-6-087]    Paper published in indexed American Journal of Health-System Pharmacy              2004                  Study conducted for 16 months, November 1999 to March 2001   Patients were randomized to enhanced care or usual care groups, for 1 year                                                                           Washington, USA              Primary care pharmacy   2                    74            To evaluate the impact of pharmacist's interventions in collaborative care to improve the care of, and outcomes for, patients with depression, to test the effectiveness of pharmacist interventions in collaboration models
  Rickles[@b19-ppa-6-087]     Paper published in indexed Journal of the American Pharmacists Association         2005                  October 1, 2001 to September 30, 2002                        Randomized, controlled, unblended, mixed experimental design                                                                                         Wisconsin, USA               Community pharmacy      14                   63            To explore the impact of telephone-based education and monitoring by community pharmacists on multiple outcomes of pharmacist-- patient collaboration
  Brook[@b20-ppa-6-087]       Paper published in indexed Journal of Psychiatric Services                         2005                  April 2000 to April 2001                                     Randomized controlled trial with 6-month follow-up                                                                                                   The Netherlands              Community pharmacy      19                   147           To improve adherence to antidepressant regimens through a pharmacist intervention
  Al-Saffar[@b21-ppa-6-087]   Paper published in indexed Journal of International Journal of Pharmacy Practice   2005                  Study conducted for 18 months, 1999 to 2001                  Randomized into a control and two treatment groups. Treatment groups additionally received a patient information leaflet                             Kuwait                       Outpatient              7                    270           To assess the acceptability and effectiveness of two educational initiatives on patterns of antidepressant medication use in depressed Kuwaiti patients
  Crockett[@b22-ppa-6-087]    Paper published in indexed The Australian Journal of Rural Health                  2006                                                                               Parallel-groups design with a control and intervention group                                                                                         New South Wales, Australia   Community pharmacy      32                   106           Documentation and evaluation of patient outcomes into the role of rural community pharmacists in the management of depression
  Rickles[@b23-ppa-6-087]     Paper published in indexed Journal of the American Pharmacists Association         2006                  October 1, 2001 to September 30, 2002                        Randomized, controlled, experimental design                                                                                                          Wisconsin, USA               Community pharmacy      14                   60            To determine whether telephone follow-up can influence the nature and extent to which antidepressant users provide feedback to pharmacists, whether patient characteristics are associated with the extent of patient feedback, how patient feedback affects subsequent outcomes after controlling for patient characteristics
  Bosmans[@b24-ppa-6-087]     Paper published in indexed Journal of PharmacoEconomics                            2007                  April 2000 to April 2001                                     An economic evaluation performed alongside a 6-month randomized controlled trial                                                                     The Netherlands              Community pharmacy      19                   88            To evaluate the cost effectiveness of a pharmacy-based intervention to improve adherence to antidepressant therapy in adult patients receiving treatment in primary care

###### 

Summary of pharmacies contact and intervention

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Total number of contact   Direct contact   Indirect contact   Total number of pharmacist intervention   Type of pharmacist intervention   Study participants   Sample size   Follow up   Rate of adherence                                  
  --------------------------- ------------------------- ---------------- ------------------ ----------------------------------------- --------------------------------- -------------------- ------------- ----------- ------------------- ---- ----- ----------- ------- -------
  Canales[@b13-ppa-6-087]     4                         4                0                  3                                         PE                                M                    DP                                            2    93    7 months    −7%     27%

                                                                                                                                                                                                                                                                  −7%     22%

  Bultman[@b14-ppa-6-087]     2                         2                0                  1                                         PE                                                                                                   23   100   2 months    87%     63%

  Finley[@b15-ppa-6-087]      8                         3                5                  3                                         PE                                                     DP            PC                              2    220   6 months    66%     81%

  Finley[@b16-ppa-6-087]      6                         1                5                  4                                         PE                                M                    DP            PC                              2    150   6 months    48%     67%

  Adler[@b17-ppa-6-087]       14                        9                5                  2                                         PE                                M                                                                  5    533   12 months   48.9%   60.6%

  Capoccia[@b18-ppa-6-087]    4                         2                2                  4                                         PE                                M                    DP            PC                              2    74    12 months   57%     59%

  Rickles[@b19-ppa-6-087]     4                         1                3                  3                                         PE                                M                                  PC                              14   63    3 months    51%     70%

  Brook[@b20-ppa-6-087]       4                         1                3                  3                                         PE                                                                   PC          THV                 19   147   6 months    73%     90%

  Al-Saffar[@b21-ppa-6-087]   4                         3                1                  1                                         PE                                                                                                   7    270   7 months    10%\    39%\
                                                                                                                                                                                                                                                                  10%     43%

  Crockett[@b22-ppa-6-087]    3                         1                2                  1                                         PE                                                                                                   32   106   2 months    96%     95%

  Rickles[@b23-ppa-6-087]     4                         1                3                  2                                         PE                                                                   PC                              14   60    3 months    51%     70%

  Bosmans[@b24-ppa-6-087]     3                         3                0                  2                                         PE                                                                               THV                 19   88    6 months    86%     88%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** PE, patients education; M, drug monitoring; DP, drug prescriptions; PC, phone call; THV, take home video.
